Search

Your search keyword '"Vincent Molinié"' showing total 21 results
Start Over Author "Vincent Molinié" Language english
21 results on '"Vincent Molinié"'

1. High prevalence of human papillomavirus infection in HIV-infected women living in French Antilles and French Guiana.

Author

Sylvie Abel, Fatiha Najioullah, Jean-Luc Voluménie, Laetitia Accrombessi, Gabriel Carles, Dominique Catherine, Déborah Chiappetta, Cyril Clavel, Akua Codjo-Sodokine, Myriam El Guedj, Janick Jean-Marie, Vincent Molinié, Sandrine Pierre-François, Sofia Stegmann-Planchard, Vincent Vantilcke, Tania Vaz, Mathieu Nacher, André Cabié, Raymond Césaire, and for HP2V study group

Subjects
Medicine, Science
Abstract

An association between HIV infection and cervical cancer, a major public health issue worldwide, has been reported. The aim of this study was to estimate the prevalence of human papillomavirus (HPV) infection and the distribution of HPV genotypes in HIV-infected women living in French Antilles and Guiana and to determine HIV-related characteristics associated with HPV infection. This cross-sectional study included 439 HIV-infected women who were followed between January 2011 and May 2014. Variables related to HIV infections were collected, and cervical samples were analysed to determine HPV genotypes. The median age of the population was 46 years. Estimated prevalence of HPV and high-risk (HR)-HPV infection were 50.1% IC95 [45.4-54.7] and 42% IC95 [37.3-46.6], respectively. HR-HPV 16, 52, 53 or intermediate risk-HPV-68 were found in 25% to 30% of the HPV-infected patients. Gynaecological screening revealed abnormal cervical smear in 24% and 42% of HR-HPV-negative and HPV-positive women, respectively (p = 0.003). Approximately 90% of women were on antiretroviral therapy (ART). Demographic characteristics associated with a higher prevalence of HPV infection included alcohol consumption. Regarding HIV-related characteristics, current therapy on ART, its duration, and undetectable plasma concentrations of RNA-HIV1 were associated with a lower risk of HPV infection. Infection rate with HR-HPV was higher than what is commonly reported in HIV-negative women worldwide and was more likely in women with incomplete HIV suppression. These results highlight the need for supporting adherence to ART, cervical cytology, HPV testing and HPV vaccination.

Published
2019
Full Text
View/download PDF

2. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.

Author

Marie Simon, Pierre-Olivier Bosset, Mathieu Rouanne, Simone Benhamou, Camelia Radulescu, Vincent Molinié, Yann Neuzillet, Xavier Paoletti, and Thierry Lebret

Subjects
Medicine, Science
Abstract

AIM:To assess the prognostic value of multiple recurrences on the risk of progression in a large cohort of TaG1 bladder cancer of low and intermediate risk based on the EORTC score and to evaluate prognostic factors of multiple recurrences. MATERIALS AND METHODS:We retrospectively analyzed a French cohort of 470 patients with primary TaG1 bladder cancer diagnosed between 1986 and 2010 and followed until 2012. They were classified at low and intermediate risk using the EORTC risk score. Associations between the number of recurrences and the risk of progression to high grade Ta/T1 bladder cancer and progression to muscle-invasive disease were assessed. The characteristics of recurrences, as occurrence time or localization, and risk of other recurrences were evaluated. RESULTS:Out of 470 patients, 251 had recurrence, 34 progressed to high grade Ta/T1 and 17 to muscle-invasive disease, including 4 who had non muscle-invasive progression first. The median follow-up was 7.2 years (interquartile range: 4.2-10.9). In half the progressions, no previous recurrence was observed. No association between the number of recurrences and the risk of progression was detected. Even after 5 years free of event, patients had a 15% risk of recurrence. History of two or more recurrences increased by 4.5 the risk of subsequent recurrence. Time between two recurrences inferior to six months and multifocal localization increased the risk of recurrence. CONCLUSION:Surveillance of patients with TaG1 should be continued beyond 5 years of follow-up. However, cystoscopy exams could be spaced after 5 years. Multiple TaG1 recurrences did not appear to be prognostic for disease progression, but increased significantly the risk of subsequent recurrences. Short time between two recurrences and multifocal localization may serve to adapt monitoring of patients with TaG1 Bladder cancer.

Published
2019
Full Text
View/download PDF

3. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis.

Author

Sylvie Rodrigues-Ferreira, Anne Di Tommaso, Ariane Dimitrov, Sylvie Cazaubon, Nadège Gruel, Hélène Colasson, André Nicolas, Nathalie Chaverot, Vincent Molinié, Fabien Reyal, Brigitte Sigal-Zafrani, Benoit Terris, Olivier Delattre, François Radvanyi, Franck Perez, Anne Vincent-Salomon, and Clara Nahmias

Subjects
Medicine, Science
Abstract

BACKGROUND: Breast cancer is a heterogeneous disease that is not totally eradicated by current therapies. The classification of breast tumors into distinct molecular subtypes by gene profiling and immunodetection of surrogate markers has proven useful for tumor prognosis and prediction of effective targeted treatments. The challenge now is to identify molecular biomarkers that may be of functional relevance for personalized therapy of breast tumors with poor outcome that do not respond to available treatments. The Mitochondrial Tumor Suppressor (MTUS1) gene is an interesting candidate whose expression is reduced in colon, pancreas, ovary and oral cancers. The present study investigates the expression and functional effects of MTUS1 gene products in breast cancer. METHODS AND FINDINGS: By means of gene array analysis, real-time RT-PCR and immunohistochemistry, we show here that MTUS1/ATIP3 is significantly down-regulated in a series of 151 infiltrating breast cancer carcinomas as compared to normal breast tissue. Low levels of ATIP3 correlate with high grade of the tumor and the occurrence of distant metastasis. ATIP3 levels are also significantly reduced in triple negative (ER- PR- HER2-) breast carcinomas, a subgroup of highly proliferative tumors with poor outcome and no available targeted therapy. Functional studies indicate that silencing ATIP3 expression by siRNA increases breast cancer cell proliferation. Conversely, restoring endogenous levels of ATIP3 expression leads to reduced cancer cell proliferation, clonogenicity, anchorage-independent growth, and reduces the incidence and size of xenografts grown in vivo. We provide evidence that ATIP3 associates with the microtubule cytoskeleton and localizes at the centrosomes, mitotic spindle and intercellular bridge during cell division. Accordingly, live cell imaging indicates that ATIP3 expression alters the progression of cell division by promoting prolonged metaphase, thereby leading to a reduced number of cells ungergoing active mitosis. CONCLUSIONS: Our results identify for the first time ATIP3 as a novel microtubule-associated protein whose expression is significantly reduced in highly proliferative breast carcinomas of poor clinical outcome. ATIP3 re-expression limits tumor cell proliferation in vitro and in vivo, suggesting that this protein may represent a novel useful biomarker and an interesting candidate for future targeted therapies of aggressive breast cancer.

Published
2009
Full Text
View/download PDF

4. RBM10-TFE3 fusions: A FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: Comprehensive study of six novel cases

Author

Béatrice Cenciu, Bérengère Dadone-Montaudié, Ilaria Di Mauro, Vincent Bland, Myriam Decaussin-Petrucci, Damien Ambrosetti, Jonathan Derman, Pierre-Alexandre Just, Nathalie Rioux-Leclercq, Claire Arbaud, Florence Pedeutour, Vincent Molinié, F. Arbib, Mathilde Sibony, Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Prime dandapos, interessement a la recherche (Direction de la Recherche et de landapos, Innovation, Nice University Hospital) Funding Source: Medline, Université Nice Sophia Antipolis (1965 - 2019) (UNS), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Oncogene Proteins, Fusion, [SDV]Life Sciences [q-bio], RBM10-TFE3, TFE3, RNA sequencing (RNAseq), Chromosomal rearrangement, Biology, 03 medical and health sciences, 0302 clinical medicine, renal cell carcinoma (RCC), Renal cell carcinoma, Genetics, medicine, Humans, Carcinoma, Renal Cell, Gene, In Situ Hybridization, Fluorescence, X chromosome, 030304 developmental biology, 0303 health sciences, medicine.diagnostic_test, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, RNA-Binding Proteins, Chromosome, medicine.disease, fluorescence in situ hybridization (FISH), Kidney Neoplasms, 3. Good health, 030220 oncology & carcinogenesis, Female, Immunostaining, Fluorescence in situ hybridization
Abstract

International audience; The accurate diagnosis of Xp11-translocation renal cell carcinoma (RCC) in adults is challenging. TFE3 (located on chromosome X) fuses with a partner gene generally located on another chromosome. In rare cases TFE3 may fuse with a neighboring gene: RBM10. Because TFE3 false-positive immunostaining is a common pitfall in many laboratories, demonstration of the chromosomal rearrangement is required in order to ascertain the diagnosis. Fluorescence in situ hybridization (FISH)-that has been considered as the gold standard method-reaches its limits for detecting small Xp11 paracentric inversions. We performed a comprehensive clinical, histological and genomic study of six novel cases of RCC with RBM10-TFE3 fusion. Using FISH, TFE3 rearrangement was equivocal in one case and negative in others. RBM10-TFE3 fusion was discovered using targeted RNA sequencing (RNASeq). As all the previously reported cases (mean age: 50), the six patients were adults (mean age: 42), suggesting an epidemiologic difference between RBM10-TFE3 RCC and tumors harboring some other partner genes, such as ASPSCR1 that rather occur in children. Array-comparative genomic hybridization showed several alterations, notably a gain of 17q in four cases with papillary features and loss of 3p in one case with clear cells. Our study demonstrates that, though rare among adult cases of RCC, RBM10-TFE3 fusion is not exceptional and warrants appropriate molecular detection. Notably, it would be worthy to systemically investigate by RNASeq challenging RCC with type-2 papillary features and 17q gain.

Published
2021
Full Text
View/download PDF

5. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey

Author

Sean R. Williamson, Matthew J Wasco, Adeboye O. Osunkoya, Maria S. Tretiakova, Ronald Araneta, Carmen M. Perrino, Virginie Verkarre, Mahmut Akgul, Joseph Sanfrancesco, Jonathan Melamed, Ankur R. Sangoi, Ted Farzaneh, Anna Caliò, Vincent Molinié, Ibrahim Kulac, Funda Vakar-Lopez, Francesca Khani, Brett Delahunt, Jeffrey S. So, Sara E. Wobker, Dilek Ertoy, Rohit Mehra, Jae Y. Ro, Martin J. Magers, Berrak Gumuskaya, Angel Panizo, Michelle S. Hirsch, George J. Netto, Ondrej Hes, Antonio Lopez-Beltran, Tipu Nazeer, Loránd L. Kis, Sounak Gupta, Steven Cristopher Smith, Pedram Argani, Victor E. Reuter, Hikmat Al-Ahmadie, Priya Rao, Muhammad T. Idrees, M Nourieh, Lara R. Harik, Liang Cheng, Debra L. Zynger, Güliz A. Barkan, Dibson Gondim, Qiu Rao, Stephanie L. Skala, Omar Hameed, Hemamali Samaratunga, and Satish K. Tickoo

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, genitourinary pathology, immunohistochemistry, kidney neoplasms, TFE3, Gastroenterology, Pathology and Forensic Medicine, Young Adult, Renal cell carcinoma, Predictive Value of Tests, Cytology, Internal medicine, Eosinophilic, medicine, Biomarkers, Tumor, Humans, Genetic Predisposition to Disease, Practice Patterns, Physicians', Child, Carcinoma, Renal Cell, In Situ Hybridization, Fluorescence, Aged, Aged, 80 and over, Gene Rearrangement, business.industry, Genitourinary system, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Infant, General Medicine, Middle Aged, medicine.disease, Staining, Pathologists, Phenotype, Child, Preschool, Health Care Surveys, Immunohistochemistry, Female, business, Epithelioid cell
Abstract

Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features.131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up.Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells with abundant cytoplasm were the most encountered cytologic feature, with either clear (almost always 10/50, 20%; frequently 34/50, 68%) or eosinophilic (almost always 4/49, 8%; frequently 28/49, 57%) cytology. Strong (3+) or diffuse (>75% of tumour cells) nuclear TFE3 IHC expression was considered diagnostic by 13/46 (28%) and 12/47 (26%) participants, respectively. Main TFE3 IHC issues were the low specificity (16/42, 38%), unreliable staining performance (15/42, 36%) and background staining (12/42, 29%). Most preferred IHC assays other than TFE3, cathepsin K and pancytokeratin were melan A (44/50, 88%), HMB45 (43/50, 86%), carbonic anhydrase IX (41/50, 82%) and CK7 (32/50, 64%). Cut-off for positive TFE3 fluorescent in situ hybridisation (FISH) was preferably 10% (9/50, 18%), although significant variation in cut-off values was present. 23/48 (48%) participants required TFE3 FISH testing to confirm TFE3-RCC regardless of the histomorphologic and IHC assessment. 28/50 (56%) participants would request additional molecular studies other than FISH assay in selected cases, whereas 3/50 participants use additional molecular cases in all cases when TFE3-RCC is in the differential.Optimal diagnostic approach on TFE3-RCC is impacted by IHC and/or FISH assay preferences as well as their conflicting interpretation methods.

Published
2021

6. pH‐Sensitive Poly(ethylene glycol)/Poly(ethoxyethyl glycidyl ether) Block Copolymers: Synthesis, Characterization, Encapsulation, and Delivery of a Hydrophobic Drug

Author

Michèle Salmain, Nicolas Illy, Philippe Guégan, Vincent Corcé, Vincent Molinié, Jéril Degrouard, Mélanie Labourel, Guillaume Tresset, Jeremy M. Zimbron, Institut Parisien de Chimie Moléculaire (IPCM), Chimie Moléculaire de Paris Centre (FR 2769), Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique des Solides (LPS), and Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)

Subjects
Polymers and Plastics, curcumin encapsulation, 02 engineering and technology, amphiphilic polyether, 010402 general chemistry, 01 natural sciences, Micelle, chemistry.chemical_compound, Amphiphile, Polymer chemistry, Materials Chemistry, Copolymer, Physical and Theoretical Chemistry, Solubility, anionic-ring opening polymerization, Aqueous solution, Organic Chemistry, self-assembly, 021001 nanoscience & nanotechnology, Condensed Matter Physics, 0104 chemical sciences, 3. Good health, [CHIM.POLY]Chemical Sciences/Polymers, [SDV.SP.PG]Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacology, chemistry, Polymerization, pH-sensitive copolymer, Curcumin, 0210 nano-technology, Ethylene glycol
Abstract

International audience; Curcumin is a natural polyphenolic compound known for its numerous pharmacological properties. However, its low water solubility and instability at neutral pH are serious drawbacks preventing its use as an oral drug. Well‐defined amphiphilic poly(ethylene glycol)‐block‐poly(ethoxyethyl glycidyl ether) (PEG‐b‐PEEGE) block copolymers carrying acid‐labile acetal groups are synthesized by anionic ring‐opening polymerization and investigated as potential pH‐sensitive nano‐carriers for delivery of curcumin to cancer cells. The nanoparticles, resulting from copolymer self‐assembly in aqueous media, are characterized by dynamic light scattering and cryo‐transmission electron microscopy. The nanoparticles’ stabilities are evaluated in three different phosphate buffers (pH = 7.2, 6.4, and 5.3). The stability decreases at lower pH and a complete disappearance of the nanoparticles is noticed after 4 days at pH 5.3. Curcumin is encapsulated in hydrophobic core of mPEG40‐b‐PEEGE25 nanoparticles allowing significant enhancements of curcumin solubility in water and lifetime at neutral pH. In vitro curcumin release is studied at different pH by UV‐spectroscopy and high‐performance liquid chromatography (HPLC). The cytotoxicity of curcumin and curcumin encapsulated in micelles is evaluated by cell viability 3‐(4,5‐Dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2H‐tetrazolium bromide (MTT) assay on MDA‐MB‐231 human breast cancer cells

Published
2019
Full Text
View/download PDF

7. High prevalence of human papillomavirus infection in HIV-infected women living in French Antilles and French Guiana

Author

Raymond Césaire, Akua Codjo-Sodokine, Fatiha Najioullah, Jean-Luc Voluménie, C Clavel, Déborah Chiappetta, Sylvie Abel, S. Stegmann-Planchard, Mathieu Nacher, Vincent Vantilcke, Dominique Catherine, Vincent Molinié, Laetitia Accrombessi, Gabriel Carles, Sandrine Pierre-François, Tania Vaz, Myriam El Guedj, André Cabié, and Janick Jean-Marie

Subjects
RNA viruses, Viral Diseases, European People, Cross-sectional study, HIV Infections, Pathology and Laboratory Medicine, Cervical Cancer, 0302 clinical medicine, Immunodeficiency Viruses, Genotype, Medicine and Health Sciences, Prevalence, Ethnicities, Public and Occupational Health, French People, 030212 general & internal medicine, Guadeloupe, Papillomaviridae, Cervical cancer, education.field_of_study, Multidisciplinary, HPV infection, virus diseases, HIV diagnosis and management, Middle Aged, Vaccination and Immunization, female genital diseases and pregnancy complications, French Guiana, Infectious Diseases, Oncology, Anti-Retroviral Agents, Medical Microbiology, Viral Pathogens, 030220 oncology & carcinogenesis, Viruses, RNA, Viral, Medicine, Female, Pathogens, Research Article, Adult, Human Papillomavirus Infection, medicine.medical_specialty, Papillomaviruses, Alcohol Drinking, Urology, Science, Immunology, Population, Sexually Transmitted Diseases, Antiretroviral Therapy, Lower risk, Microbiology, 03 medical and health sciences, Antiviral Therapy, Internal medicine, Retroviruses, medicine, Humans, Human papillomavirus, education, Microbial Pathogens, Genitourinary Infections, business.industry, Public health, Lentivirus, Papillomavirus Infections, Organisms, Biology and Life Sciences, HIV, Human Papillomavirus, Cancers and Neoplasms, medicine.disease, Diagnostic medicine, Cross-Sectional Studies, People and Places, HIV-1, Population Groupings, Preventive Medicine, DNA viruses, business, Gynecological Tumors
Abstract

An association between HIV infection and cervical cancer, a major public health issue worldwide, has been reported. The aim of this study was to estimate the prevalence of human papillomavirus (HPV) infection and the distribution of HPV genotypes in HIV-infected women living in French Antilles and Guiana and to determine HIV-related characteristics associated with HPV infection. This cross-sectional study included 439 HIV-infected women who were followed between January 2011 and May 2014. Variables related to HIV infections were collected, and cervical samples were analysed to determine HPV genotypes. The median age of the population was 46 years. Estimated prevalence of HPV and high-risk (HR)-HPV infection were 50.1% IC95 [45.4-54.7] and 42% IC95 [37.3-46.6], respectively. HR-HPV 16, 52, 53 or intermediate risk-HPV-68 were found in 25% to 30% of the HPV-infected patients. Gynaecological screening revealed abnormal cervical smear in 24% and 42% of HR-HPV-negative and HPV-positive women, respectively (p = 0.003). Approximately 90% of women were on antiretroviral therapy (ART). Demographic characteristics associated with a higher prevalence of HPV infection included alcohol consumption. Regarding HIV-related characteristics, current therapy on ART, its duration, and undetectable plasma concentrations of RNA-HIV1 were associated with a lower risk of HPV infection. Infection rate with HR-HPV was higher than what is commonly reported in HIV-negative women worldwide and was more likely in women with incomplete HIV suppression. These results highlight the need for supporting adherence to ART, cervical cytology, HPV testing and HPV vaccination.

Published
2019

8. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

Author

Olivier Caron, Etienne Rouleau, Hamida Mohamdi, F. Boitier, Jean-Luc Perrot, Eve Maubec, Arnaud de la Fouchardière, Stéphane Richard, Pierre Vabres, Luc Thomas, Rosette Lidereau, Simon Saule, Diana Zelenika, Pilar Galan, Tanguy Martin-Denavit, Lorenza Pastorino, N. Poulalhon, Jérôme Couturier, Bruno Labeille, Eve Corda, Caroline Robert, Philippe Dessen, Marie-Françoise Avril, Bernard Escudier, Christian Ingvar, Sandy Giuliano, Celia Badenas, Robert Ballotti, Benoit d’Hayer, Gilbert M. Lenoir, Betty Gardie, Stéphane Dalle, Laurence Brugières, Brigitte Bressac-de Paillerets, Audrey Remenieras, Valérie Chaudru, Paola Ghiorzo, Hélène Blanché, Philippe Bahadoran, Fabienne Lesueur, Håkan Olsson, Bin Tean Teh, Philippe Vielh, Corine Bertolotto, Pascale Andry-Benzaquen, Thomas Strub, Florence Demenais, Vincent Molinié, Mahaut de Lichy, Susana Puig, Karine Bille, Sophie Gad, Annick Rossi, Mark Lathrop, Nicolas Dupin, Irwin Davidson, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
0301 basic medicine, Mutation, Multidisciplinary, Melanoma, Carcinoma, SUMO protein, Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, medicine.disease_cause, medicine.disease, Microphthalmia-associated transcription factor, 3. Good health, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Germline mutation, medicine, Cancer research, Epigenetics, 030217 neurology & neurosurgery, ComputingMilieux_MISCELLANEOUS
Abstract

Nature 480, 94–98 (2011); doi:10.1038/nature10539 In this Letter, one image was mistakenly duplicated during preparation of the artwork. In the original Fig. 3d, the left image illustrating migration of RCC4 cells transduced with empty adenovirus (EV) at 24 h is a duplicate of the middle image showing migration of RCC4 cells transduced with an adenovirus encoding Mi-WT.

Published
2016
Full Text
View/download PDF

9. Molecular subtypes of clear cell renal cell carcinoma are associated to sunitinib response in the metastatic setting

Author

Reza Elaidi, Virginie Verkarre, Catherine Sautès-Fridman, Gabrielle Couchy, Stéphane Oudard, Aurélien de Reyniès, Wolf H. Fridman, Etienne Becht, Jessica Zucman-Rossi, Mathilde Sibony, Nathalie Rioux-Leclercq, Sylvie Job, Alexandra Karadimou, Corinne Teghom, Jean Jacques Patard, Benoit Beuselinck, Vincent Molinié, Nicolas A. Giraldo, Arnaud Mejean, Service d'Anatomie et de Cytologie Pathologiques, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), PremUp Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Descartes - Paris 5 (UPD5)-CHI Créteil-Institut de Recherche pour le Développement (IRD)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Labex Immuno-oncology, Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-PRES Sorbonne Paris Cité-Faculté de Médecine, Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'anatomie pathologique, Hôpital Saint Joseph, Service d'anatomie pathologique [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire d'Immunologie Cellulaire et Clinique, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR58-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), (le programme) Cartes d'identité des tumeurs (CIT), Ligue Nationales Contre le Cancer (LNCC), Service d'oncologie médicale [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut de Recherche pour le Développement (IRD)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7)-CHI Créteil-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Universités-Université Paris Descartes - Paris 5 (UPD5)-CHI Créteil-Institut de Recherche pour le Développement (IRD)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-PRES Sorbonne Paris Cité-Faculté de Médecine, Service d'anatomie et cytologie pathologiques [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Programme'Cartes d'Identité des Tumeurs ' (CIT), Ligue Nationale Contre le Cancer, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Sorbonne Universités-Université Paris Descartes - Paris 5 ( UPD5 ) -CHI Créteil-Institut de Recherche pour le Développement ( IRD ) -Université Paris-Sud - Paris 11 ( UP11 ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Diderot - Paris 7 ( UPD7 ), Genomique Fonctionnelle des Tumeurs Solides, Université Paris Diderot - Paris 7 ( UPD7 ) -IFR105-Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -PRES Sorbonne Paris Cité-Faculté de Médecine, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes ( IGDR ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Centre National de la Recherche Scientifique ( CNRS ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -IFR58-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Programme'Cartes d'Identité des Tumeurs ' ( CIT ), and Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP )

Subjects
Male, Cancer Research, Pathology, medicine.medical_specialty, Indoles, [SDV]Life Sciences [q-bio], Angiogenesis Inhibitors, Antineoplastic Agents, Gene mutation, urologic and male genital diseases, Disease-Free Survival, PBRM1, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Sunitinib, Carcinoma, medicine, Humans, Pyrroles, Carcinoma, Renal Cell, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, [ SDV ] Life Sciences [q-bio], business.industry, Gene Expression Profiling, Cancer, medicine.disease, Vascular Endothelial Growth Factor Receptor-2, Kidney Neoplasms, 3. Good health, Clear cell renal cell carcinoma, Treatment Outcome, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Cancer research, Female, business, Tyrosine kinase, medicine.drug
Abstract

Purpose: Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our aim was to identify molecular markers associated with outcome in patients with m-ccRCC treated with sunitinib. Experimental Design: We performed global transcriptome analyses on 53 primary resected ccRCC tumors from patients who developed metastatic disease and were treated with first-line sunitinib. We also determined chromosome copy-number aberrations, methylation status, and gene mutations in von Hippel–Lindau and PBRM1. Molecular data were analyzed in relation with response rate (RR), progression-free survival (PFS), and overall survival (OS). Validation was performed in 47 additional ccRCC samples treated in first-line metastatic setting with sunitinib. Results: Unsupervised transcriptome analysis identified 4 robust ccRCC subtypes (ccrcc1 to 4) related to previous molecular classifications that were associated with different responses to sunitinib treatment. ccrcc1/ccrcc4 tumors had a lower RR (P = 0.005) and a shorter PFS and OS than ccrcc2/ccrcc3 tumors (P = 0.001 and 0.0003, respectively). These subtypes were the only significant covariate in the multivariate Cox model for PFS and OS (P = 0.017 and 0.006, respectively). ccrcc1/ccrcc4 tumors were characterized by a stem-cell polycomb signature and CpG hypermethylation, whereas ccrcc3 tumors, sensitive to sunitinib, did not exhibit cellular response to hypoxia. Moreover, ccrcc4 tumors exhibited sarcomatoid differentiation with a strong inflammatory, Th1-oriented but suppressive immune microenvironment, with high expression of PDCD1 (PD-1) and its ligands. Conclusions: ccRCC molecular subtypes are predictive of sunitinib response in metastatic patients, and could be used for personalized mRCC treatment with TKIs, demethylating or immunomodulatory drugs. Clin Cancer Res; 21(6); 1329–39. ©2015 AACR.

Published
2015
Full Text
View/download PDF

10. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

Author

Elodie Chapeaublanc, François Radvanyi, Dimitri Vordos, Yves Denoux, Simone Benhamou, Pascale Soyeux, Isabelle Bernard-Pierrot, Nabila Elarouci, Aurélie Hérault, Yann Neuzillet, Mathilde Sibony, Fabien Reyal, Pascale Maillé, Vincent Molinié, Eric Letouzé, Aurélie Caillault, Xavier Paoletti, Karina Ofualuka, Jennifer Southgate, Thierry Lebret, Aurélien de Reyniès, Sandra Rebouissou, Anne Biton, Clémentine Krucker, Aurélie Kamoun, Yves Allory, May-Linda Lepage, Agnès Laplanche, Université Paris Descartes - Paris 5 (UPD5), Compartimentation et dynamique cellulaires (CDC), Institut Curie [Paris]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), (le programme) Cartes d'identité des tumeurs (CIT), Ligue Nationales Contre le Cancer (LNCC), Biologie Cellulaire et Cancer, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), Ligue Nationale Contre le Cancer - Paris, Ligue Nationale Contre le Cancer (LNCC), Service d'Hématologie Cellulaire [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), 'Cartes d'Identité des Tumeurs ' program (CIT), FLIRT, Fédération pour L'étude de l'Ischémie Reperfusion en Transplantation, Service d'anatomie pathologique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Plateforme de Ressources Biologiques, Département de pathologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Chirurgie Oncologique, and Institut Curie [Paris]

Subjects
Adult, Hepatocyte Nuclear Factor 3-alpha, Male, Oncology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Transcriptome, Mice, Cell Line, Tumor, Internal medicine, medicine, Carcinoma, Animals, Humans, Neoplasm Invasiveness, Molecular Targeted Therapy, Epidermal growth factor receptor, Autocrine signalling, Protein Kinase Inhibitors, Survival analysis, Aged, Cell Proliferation, Aged, 80 and over, Bladder cancer, biology, Cell growth, Muscles, General Medicine, Middle Aged, medicine.disease, Survival Analysis, Phenotype, ErbB Receptors, Gene Expression Regulation, Neoplastic, Autocrine Communication, Treatment Outcome, Urinary Bladder Neoplasms, biology.protein, Keratins, Female, Butylhydroxybutylnitrosamine, Signal Transduction
Abstract

Muscle-invasive bladder carcinoma (MIBC) constitutes a heterogeneous group of tumors with a poor outcome. Molecular stratification of MIBC may identify clinically relevant tumor subgroups and help to provide effective targeted therapies. From seven series of large-scale transcriptomic data (383 tumors), we identified an MIBC subgroup accounting for 23.5% of MIBC, associated with shorter survival and displaying a basal-like phenotype, as shown by the expression of epithelial basal cell markers. Basal-like tumors presented an activation of the epidermal growth factor receptor (EGFR) pathway linked to frequent EGFR gains and activation of an EGFR autocrine loop. We used a 40-gene expression classifier derived from human tumors to identify human bladder cancer cell lines and a chemically induced mouse model of bladder cancer corresponding to human basal-like bladder cancer. We showed, in both models, that tumor cells were sensitive to anti-EGFR therapy. Our findings provide preclinical proof of concept that anti-EGFR therapy can be used to target a subset of particularly aggressive MIBC tumors expressing basal cell markers and provide diagnostic tools for identifying these tumors.

Published
2014
Full Text
View/download PDF

11. A Case of Adrenal Metastasis in Seminoma

Author

Zakaria, Bouabdallah, Pierre-Etienne, Théveniaud, Véronique, Duchatelle, Vincent, Molinié, Walid, Massoud, and Hervé, Baumert

Subjects
Article Subject
Abstract

We report an uncommon case of testicular cancer with adrenal metastasis without retroperitoneal or distant metastatic disease. This situation is highly unusual. In fact, no similar case was reported in the literature. Our case is the first adrenalectomy that has been performed for secondary localization of testicular cancer. After eighteen-month followup, the patient was doing well, with no evidence of disease.

Published
2013
Full Text
View/download PDF

12. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma

Author

Min-Han Tan, Jun Sugimura, Jonathon A. Ditlev, Annick Vieillefond, Tomoaki Fujioka, Puay Hoon Tan, Ximing J. Yang, Daisuke Matsuda, Delphine Amsellem-Ouazana, Eric J. Kort, Nicolas Thiounn, Chin Fong Wong, Sophie Giraud, Philippe Vielh, Thierry Flam, Bin Tean Teh, Bernard Debré, Stéphane Richard, Sophie Ferlicot, Marc Zerbib, Kyle A. Furge, Sok Kean Khoo, Hwei Ling Tan, Gérard Benoit, Vincent Molinié, Stéphane Droupy, BMC, Ed., Laboratory of Cancer Genetics, Van Andel Institute [Grand Rapids], NCCS-VARI Translational Cancer Research Laboratory, National Cancer Centre Singapore, Department of Medical Oncology, Department of Epidemiology and Public Health, National University of Singapore (NUS), Department of Pathology, Singapore General Hospital, Northwestern University Feinberg School of Medicine, Department of Urology, Iwate Medical University School of Medicine, Laboratory of Computational Biology, Laboratory of Molecular Epidemiology, Laboratoire de Génétique, Hôpital Herriot, Laboratoire d'Anatomie Pathologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital de Bicêtre, Pathologie morphologique, Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service d'urologie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cytokines et Immunologie des Tumeurs Humaines (U753), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anatomie pathologique, Hôpital Saint Joseph, Laboratoire d'anatomie pathologique, Consultation d'oncogénétique spécialisée, Hôpital de Bicêtre-Service d'Urologie, and We wish to thank the Fischer Family Foundation, the Singapore Cancer Society, the French National Cancer Institute (Kidney PNES, INCa), and the French League against Cancer (Comités du Cher et de l'Indre) for supporting this study. We would also like to thank the Hauenstein Foundation and the Van Andel Foundation for their continued support. We thank the Cooperative Human Tissue Network (CHTN) of the National Cancer Institute for providing samples for analysis. Min-Han Tan is supported by the Singapore Millenium Foundation and the National Kidney Foundation.

Subjects
Pathology, Cancer Research, Chromophobe Renal Cell Carcinoma, Gene Dosage, Chromophobe cell, urologic and male genital diseases, MESH: Gene Dosage, 0302 clinical medicine, Odds Ratio, Adenoma, Oxyphilic, Oncocytoma, Gene Regulatory Networks, MESH: Nerve Tissue Proteins, Renal oncocytoma, MESH: Gene Regulatory Networks, Oligonucleotide Array Sequence Analysis, Synaptogyrins, 0303 health sciences, MESH: Genetic Testing, MESH: Polymorphism, Single Nucleotide, MESH: Carcinoma, Renal Cell, MESH: Gene Expression Regulation, Neoplastic, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunohistochemistry, MESH: Predictive Value of Tests, Kidney Neoplasms, MESH: Reproducibility of Results, Gene Expression Regulation, Neoplastic, Oncology, Chromosomes, Human, Pair 1, 030220 oncology & carcinogenesis, Cytogenetic Analysis, MESH: Membrane Proteins, Research Article, medicine.medical_specialty, MESH: Adenoma, Oxyphilic, MESH: Chromosomes, Human, Pair 1, [SDV.CAN]Life Sciences [q-bio]/Cancer, Nerve Tissue Proteins, Computational biology, Biology, Gene dosage, Polymorphism, Single Nucleotide, lcsh:RC254-282, Diagnosis, Differential, 03 medical and health sciences, MESH: Gene Expression Profiling, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Diagnosis, Differential, Predictive Value of Tests, medicine, Genetics, Biomarkers, Tumor, Humans, MESH: Tumor Suppressor Proteins, Genetic Testing, Carcinoma, Renal Cell, 030304 developmental biology, MESH: Humans, MESH: Cytogenetic Analysis, Gene Expression Profiling, Tumor Suppressor Proteins, MESH: Aquaporin 6, Membrane Proteins, Reproducibility of Results, MESH: Immunohistochemistry, Gene signature, medicine.disease, MESH: Odds Ratio, Aquaporin 6, Gene expression profiling, Clear cell renal cell carcinoma, MESH: Tumor Markers, Biological, MESH: Oligonucleotide Array Sequence Analysis, MESH: Kidney Neoplasms
Abstract

Background Chromophobe renal cell carcinoma (chRCC) and renal oncocytoma are two distinct but closely related entities with strong morphologic and genetic similarities. While chRCC is a malignant tumor, oncocytoma is usually regarded as a benign entity. The overlapping characteristics are best explained by a common cellular origin, and the biologic differences between chRCC and oncocytoma are therefore of considerable interest in terms of carcinogenesis, diagnosis and clinical management. Previous studies have been relatively limited in terms of examining the differences between oncocytoma and chromophobe RCC. Methods Gene expression profiling using the Affymetrix HGU133Plus2 platform was applied on chRCC (n = 15) and oncocytoma specimens (n = 15). Supervised analysis was applied to identify a discriminatory gene signature, as well as differentially expressed genes. High throughput single-nucleotide polymorphism (SNP) genotyping was performed on independent samples (n = 14) using Affymetrix GeneChip Mapping 100 K arrays to assess correlation between expression and gene copy number. Immunohistochemical validation was performed in an independent set of tumors. Results A novel 14 probe-set signature was developed to classify the tumors internally with 93% accuracy, and this was successfully validated on an external data-set with 94% accuracy. Pathway analysis highlighted clinically relevant dysregulated pathways of c-erbB2 and mammalian target of rapamycin (mTOR) signaling in chRCC, but no significant differences in p-AKT or extracellular HER2 expression was identified on immunohistochemistry. Loss of chromosome 1p, reflected in both cytogenetic and expression analysis, is common to both entities, implying this may be an early event in histogenesis. Multiple regional areas of cytogenetic alterations and corresponding expression biases differentiating the two entities were identified. Parafibromin, aquaporin 6, and synaptogyrin 3 were novel immunohistochemical markers effectively discriminating the two pathologic entities. Conclusions Gene expression profiles, high-throughput SNP genotyping, and pathway analysis effectively distinguish chRCC from oncocytoma. We have generated a novel transcript predictor that is able to discriminate between the two entities accurately, and which has been validated both in an internal and an independent data-set, implying generalizability. A cytogenetic alteration, loss of chromosome 1p, common to renal oncocytoma and chRCC has been identified, providing the opportunities for identifying novel tumor suppressor genes and we have identified a series of immunohistochemical markers that are clinically useful in discriminating chRCC and oncocytoma.

Published
2010
Full Text
View/download PDF

13. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis

Author

François Radvanyi, Hélène Colasson, Sylvie Rodrigues-Ferreira, Fabien Reyal, Vincent Molinié, Brigitte Sigal-Zafrani, Benoit Terris, Olivier Delattre, André Nicolas, Clara Nahmias, Franck Perez, Nathalie Chaverot, Anne Vincent-Salomon, Anne Di Tommaso, Sylvie Cazaubon, Ariane Dimitrov, and Nadège Gruel

Subjects
CA15-3, medicine.medical_treatment, Cell Biology/Cell Growth and Division, Mitosis, CA 15-3, lcsh:Medicine, Breast Neoplasms, Mice, SCID, Biology, Bioinformatics, Targeted therapy, Mice, Breast cancer, Cell Biology/Cytoskeleton, Carcinoma, medicine, Animals, Humans, Gene silencing, Neoplasm Invasiveness, lcsh:Science, Cell Proliferation, Multidisciplinary, Cell growth, Tumor Suppressor Proteins, lcsh:R, Chromosome Mapping, Prognosis, medicine.disease, Gene Expression Regulation, Neoplastic, Oncology/Breast Cancer, Cancer research, Female, lcsh:Q, Carrier Proteins, Chromosomes, Human, Pair 8, HeLa Cells, Research Article
Abstract

Background Breast cancer is a heterogeneous disease that is not totally eradicated by current therapies. The classification of breast tumors into distinct molecular subtypes by gene profiling and immunodetection of surrogate markers has proven useful for tumor prognosis and prediction of effective targeted treatments. The challenge now is to identify molecular biomarkers that may be of functional relevance for personalized therapy of breast tumors with poor outcome that do not respond to available treatments. The Mitochondrial Tumor Suppressor (MTUS1) gene is an interesting candidate whose expression is reduced in colon, pancreas, ovary and oral cancers. The present study investigates the expression and functional effects of MTUS1 gene products in breast cancer. Methods and Findings By means of gene array analysis, real-time RT-PCR and immunohistochemistry, we show here that MTUS1/ATIP3 is significantly down-regulated in a series of 151 infiltrating breast cancer carcinomas as compared to normal breast tissue. Low levels of ATIP3 correlate with high grade of the tumor and the occurrence of distant metastasis. ATIP3 levels are also significantly reduced in triple negative (ER- PR- HER2-) breast carcinomas, a subgroup of highly proliferative tumors with poor outcome and no available targeted therapy. Functional studies indicate that silencing ATIP3 expression by siRNA increases breast cancer cell proliferation. Conversely, restoring endogenous levels of ATIP3 expression leads to reduced cancer cell proliferation, clonogenicity, anchorage-independent growth, and reduces the incidence and size of xenografts grown in vivo. We provide evidence that ATIP3 associates with the microtubule cytoskeleton and localizes at the centrosomes, mitotic spindle and intercellular bridge during cell division. Accordingly, live cell imaging indicates that ATIP3 expression alters the progression of cell division by promoting prolonged metaphase, thereby leading to a reduced number of cells ungergoing active mitosis. Conclusions Our results identify for the first time ATIP3 as a novel microtubule-associated protein whose expression is significantly reduced in highly proliferative breast carcinomas of poor clinical outcome. ATIP3 re-expression limits tumor cell proliferation in vitro and in vivo, suggesting that this protein may represent a novel useful biomarker and an interesting candidate for future targeted therapies of aggressive breast cancer.

Published
2009

14. Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma

Author

Sophie Gad, Y. Denoux, Marc Zerbib, A. Mejean, Sophie Ferlicot, Annick Vieillefond, J M Hervé, S H Lefèvre, Brigitte Bressac-de Paillerets, Yves Chretien, G Allègre, Nicolas Thiounn, Sok Kean Khoo, Viorel Vasiliu, Stéphane Richard, Bin Tean Teh, Gérard Benoit, S. Giraud, and Vincent Molinié

Subjects
Cancer Research, Pathology, medicine.medical_specialty, endocrine system diseases, Chromophobe Renal Cell Carcinoma, Chromophobe cell, Biology, Polymorphism, Single Nucleotide, polymorphism, Tumor suppressor proteins, Renal cell carcinoma, Proto-Oncogene Proteins, TP53 Genes, Carcinoma, medicine, Humans, Oncocytoma, TP53, Carcinoma, Renal Cell, neoplasms, Hepatocyte Nuclear Factor 1-beta, chromophobe renal cell carcinoma, business.industry, General surgery, Tumor Suppressor Proteins, Cancer, Large series, Proteins, Genetics and Genomics, Genes, p53, medicine.disease, Kidney Neoplasms, Chromosome 17 (human), BHD, HNF1β, Oncology, Mutation, Erratum, business, Kidney cancer, Clear cell
Abstract

Correction to: British Journal of Cancer (2006) 96, 336–340. doi:10.1038/6603492 Owing to a publishing error, part of the intended Supplementary Material for this paper was omitted at the time of publication. The correct supplementary tables were published; however, a further document was omitted. We are now happy to include this document as part of the Supplementary Material online – please visit the British Journal of Cancer website (http://www.

Published
2007

15. Epidemiologic, Clinical, Ultrasonographic, and Cytological Features of Thyroid Nodules in Predicting Malignancy Risk: A Retrospective Study of 442 French Afro-Caribbean Patients

Author

Johan Joseph-Auguste, Lucien Lin, Magalie Demar, Olivier Duffas, Vincent Molinie, Caroline Sulpicy, Marie-Josée Dorival, Olivier Luxembourger, and Nadia Sabbah

Subjects
Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Objective. To evaluate epidemiologic, clinical, cytological, and ultrasonographic features of thyroid nodules in a sample French Afro-Caribbean population to determine if the standard criteria for predicting malignancy risk are applicable to this specific ethnic population. Methods and Design. This retrospectively designed study consisted of 442 patients who had consulted with the Endocrinology Department in Martinique (French overseas department) between 2007 and 2011. Of the 442 patients, 641 ultrasound-guided fine-needle aspirations (US-FNA) were performed by two experienced endocrinologists, and 212 patients underwent surgery. The geographical situation, age, gender of the patient, clinical and ultrasonographic features, TSH level, and US-FNA results were considered and cross-referenced with their pathology results. Results. The overall malignancy rate on final histopathology was 9% (women only), 80% of which were papillary cancer, and 20% were follicular cancer. Occult micropapillary carcinoma represented 35% of the papillary cancer. There was no significant difference in age, nodule localization, number of nodules, or thyroid function test between benign and malignant nodules. Contrary to the literature, we found only 12% incidentaloma in our series, while more than half of the nodules were discovered on palpation or as a clinical symptom. Hypoechogenicity in solid pattern nodules and nodules between 2 and 3 cm in size revealed a high diagnostic value in detecting malignancy. The corresponding rate of malignancy on Bethesda system histopathologic examination was as follows: 0% in undiagnosed (I), 0% benign (II) (micropapillary), 5% (FLUS)/atypia (III), 9% follicular neoplasm (IV), 33% suspected malignancy (V), and no malignant cytology (VI). These results show a different Bethesda system predictive value for this French Afro-Caribbean population. Conclusion. Studies evaluating ethnic cancer disparities among patients with thyroid cancer are limited and do not specifically focus on the French Afro-Caribbean population. Despite rare thyroid incidentaloma, 35% of the papillary cancer cases were micropapillary carcinoma, and the incidence and standardized mortality rate in Martinique are lower than in metropolitan France. The malignant risk distribution of thyroid FNA Bethesda classification in this sample population differs from the standard risk, and it is necessary to take that into account in the decision to operate by associating it with echographic malignancy criteria.

Published
2020
Full Text
View/download PDF

16. Predictors of abnormal cytology among HPV-infected women in remote territories of French Guiana

Author

Antoine Adenis, Valentin Dufit, Maylis Douine, Jerome Ponty, Laure Bianco, Fatiha Najioullah, Odile Kilié, Dominique Catherine, Nadia Thomas, Jean Luc Deshayes, Paul Brousse, Gabriel Carles, Claire Grenier, Vincent Lacoste, Vincent Molinie, Raymond Cesaire, and Mathieu Nacher

Subjects
Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270
Abstract

Abstract Background Cervical cancer prevention using cervical cytology is insufficiently sensitive, a significant proportion of HPV-infected women having normal cytology. The objective of the present study was to try to identify factors associated with abnormal cytology in HPV-infected women living in remote areas of French Guiana. Methods A study was conducted in women aged 20–65 years having HPV infections confirmed by HPV DNA detection using the GREINER-BIO-ONE kit. In addition to HPV testing, cytology was performed and classified as normal or abnormal. Demographic and life history variables, and infecting genotypes were compared between the normal and abnormal cytology groups. Results None of the demographic and life history variables were associated with cytology results. HPV genotype 53 was significantly associated with absence of cytological abnormalities whereas HPV 52, 58, 16 and perhaps 33 and 66 were independently associated with a greater risk of cytological abnormalities. When grouping HPV genotypes in different species, only species 9 (HPV 16, 31, 33, 35, 52, 58, 67) was significantly associated with abnormal cytology AOR = 5.1 (95% CI = 2.3–11.2), P

Published
2018
Full Text
View/download PDF

17. The singular epidemiology of HPV infection among French Guianese women with normal cytology

Author

Antoine Adenis, Valentin Dufit, Maylis Douine, Fatiha Najioullah, Vincent Molinie, Dominique Catherine, Odile Kilié, Nadia Thomas, Jean Luc Deshayes, Paul Brousse, Hatem Ben Amor, Remy Pignoux, Gabriel Carles, Claire Grenier, Vincent Lacoste, Raymond Cesaire, and Mathieu Nacher

Subjects
Human papillomavirus, Genotype, Normal cytology, Prevalence, French Guiana, Public aspects of medicine, RA1-1270
Abstract

Abstract Background In French Guiana, cervical cancer is the second most frequent cancer in females. The objective of the present study was to describe the prevalence of HPV infections in women with normal cervical cytology living in the remote villages of French Guiana. Methods Before the study, the study team communicated in the remote villages on the importance of screening. All women from the target population were offered to participate. They signed informed consent during inclusion and then had a concomitant HPV-test and cervical smear. Only women with normal cytology and a good quality smear were analyzed. The detection of HPV-DNA was performed using the GREINER-BIO-ONE kit. Results Overall, 27.2% of women with normal cervical cytology had a positive HPV-test. There was a U-shaped evolution of prevalence with women over 50 years having the highest HPV prevalence, followed by the 20 to 29 years group. The most prevalent HPV genotypes were HPV 53(3.52%), 68(3.33%), 52(2.59%), 31(2.22%) and 16 (1.85%). The proportion of HPV 16 among HPV-infected women was 6.8%. Conclusions HPV prevalence in cytologically normal women was very high. The most prevalent genotypes were very different from what is usually described in the world, and notably in South America.

Published
2017
Full Text
View/download PDF

19. An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma

Author

David Petillo, Kyle A. Furge, Bernice Wong Hui Min, Min-Han Tan, Betty Gardie, Ming Zhou, Ximing J. Yang, Stéphane Richard, Douglas Whitten, Vincent Molinié, Jing Chii Wong, Puay Hoon Tan, Douglas Roossien, Aikseng Ooi, Victoria Perrier-Trudova, Zhongfa Zhang, and Bin Tean Teh

Subjects
Cancer Research, NF-E2-Related Factor 2, Aldo-Keto Reductases, Biology, Response Elements, medicine.disease_cause, Antioxidants, Fumarate Hydratase, Aldehyde Reductase, Cell Line, Tumor, Null cell, medicine, Humans, RNA, Messenger, Carcinoma, Renal Cell, Gene, Genetics, Gene knockdown, Mutation, Kelch-Like ECH-Associated Protein 1, Papillary renal cell carcinomas, Nuclear Respiratory Factor 1, Intracellular Signaling Peptides and Proteins, Cell Biology, Hypoxia-Inducible Factor 1, alpha Subunit, Phenotype, Kidney Neoplasms, Gene Expression Regulation, Neoplastic, Oncology, Fumarase, Cancer research, Hereditary leiomyomatosis and renal cell carcinoma
Abstract

Summary Fumarate hydratase ( FH ) mutation causes hereditary type 2 papillary renal cell carcinoma (PRCC2). The main effect of FH mutation is fumarate accumulation. The current paradigm posits that the main consequence of fumarate accumulation is HIF-α stabilization. Paradoxically, FH mutation differs from other HIF-α stabilizing mutations, such as VHL and SDH mutations, in its associated tumor types. We identified that fumarate can directly up-regulate antioxidant response element (ARE)–controlled genes. We demonstrated that aldo-keto reductase family 1 member B10 ( AKR1B10 ) is an ARE-controlled gene and is up-regulated upon FH knockdown as well as in FH null cell lines. AKR1B10 overexpression is also a prominent feature in both hereditary and sporadic PRCC2. This phenotype better explains the similarities between hereditary and sporadic PRCC2.

Full Text
View/download PDF

20. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.

Author

Yann Neuzillet, Xavier Paoletti, Slah Ouerhani, Pierre Mongiat-Artus, Hany Soliman, Hugues de The, Mathilde Sibony, Yves Denoux, Vincent Molinie, Aurélie Herault, May-Linda Lepage, Pascale Maille, Audrey Renou, Dimitri Vordos, Claude-Clément Abbou, Ashraf Bakkar, Bernard Asselain, Nadia Kourda, Amel El Gaaied, Karen Leroy, Agnès Laplanche, Simone Benhamou, Thierry Lebret, Yves Allory, and François Radvanyi

Subjects
Medicine, Science
Abstract

TP53 and FGFR3 mutations are the most common mutations in bladder cancers. FGFR3 mutations are most frequent in low-grade low-stage tumours, whereas TP53 mutations are most frequent in high-grade high-stage tumours. Several studies have reported FGFR3 and TP53 mutations to be mutually exclusive events, whereas others have reported them to be independent. We carried out a meta-analysis of published findings for FGFR3 and TP53 mutations in bladder cancer (535 tumours, 6 publications) and additional unpublished data for 382 tumours. TP53 and FGFR3 mutations were not independent events for all tumours considered together (OR = 0.25 [0.18-0.37], p = 0.0001) or for pT1 tumours alone (OR = 0.47 [0.28-0.79], p = 0.0009). However, if the analysis was restricted to pTa tumours or to muscle-invasive tumours alone, FGFR3 and TP53 mutations were independent events (OR = 0.56 [0.23-1.36] (p = 0.12) and OR = 0.99 [0.37-2.7] (p = 0.35), respectively). After stratification of the tumours by stage and grade, no dependence was detected in the five tumour groups considered (pTaG1 and pTaG2 together, pTaG3, pT1G2, pT1G3, pT2-4). These differences in findings can be attributed to the putative existence of two different pathways of tumour progression in bladder cancer: the CIS pathway, in which FGFR3 mutations are rare, and the Ta pathway, in which FGFR3 mutations are frequent. TP53 mutations occur at the earliest stage of the CIS pathway, whereas they occur would much later in the Ta pathway, at the T1G3 or muscle-invasive stage.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results